Albany, NY -- (SBWIRE) -- 11/19/2018 -- DelveInsight has announced the addition of the "Niemann-Pick Disease Type C (NP-C) Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of NP-C for the seven major markets i.e., United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan. The Report covers the overview, treatment practice and NP-C forecasted epidemiology from 2018 to 2027 segmented by the seven major markets.

Request for sample pages

Niemann-Pick Disease Type C (NP-C) is a progressive, irreversible, pan-ethnic and chronically debilitating neurovisceral Lysosomal Lipid Storage Disease, which is characterized by the visceral, neurological and psychiatric manifestations. It involves the unique abnormalities of intracellular transport of endocytosed cholesterol with sequestration of unesterified cholesterol in lysosomes and late endosomes. The disease occurs due to the alterations in trafficking of endocytosed cholesterol. It ultimately results in the accumulation of cholesterol and glycosphingolipids in various neurovisceral tissues.

The prevalence of NP-C is similar in both male and female and NP-C in Western Europe (France, UK, and Germany) was estimated to be approximately 1/120,000 to 1/150,000 living births, based on diagnostic data. DelveInsight also estimates a higher prevalence of NP-C in the United States with approximately 1000 cases in 2016, followed by EU5 and Japan. Among the EU5 countries, Germany had the highest prevalent population of NP-C with 250 cases, followed by the UK. Spain had the lowest prevalent population in 2016. The diagnosis rate of NP-C in the 7MM is assessed to be around 50% and is expected to increase in the coming years resulting in increased diagnosed population and ultimately higher treatable cases.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. Orphazyme
2. Mallinckrodt
3. CTD Holdings
And many others

Drugs covered

1. VTS-270
2. Arimoclomol
3. Trappsol Cyclo
And many others

Report Scope

The report covers a descriptive overview of the NP-C, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the NP-C and its treatment in the 7 MM, covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for NP-C are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted NP-C market is included in the report, covering drug outreach in the 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global NP-C market